ImmunoGen's mirvetuximab soravtansine shows positive effect in Phase 1/2 ovarian cancer study; shares up 12% premarket March 26, 2018 by True Academy Comments are off Posted in:Stock Market & Investment NewsTagged with:Buy Sell ShareFTSEKLCIMalaysiaPelaburanSahamShare Trading See more Prev:Susquehanna downgrades AMD Back: All Posts Next:Lowe's announces CEO succession plan